Ibutamoren – MK-677 10mg
Ibutamoren is presented in the ORYVION catalog as a tablet formulation containing 10mg of MK-677 per tablet, supplied in containers of 50 tablets. Ibutamoren is an investigational, orally active growth hormone secretagogue that mimics the activity of ghrelin.
Its mechanism of action involves activating the ghrelin receptor, stimulating growth hormone release and increasing circulating insulin-like growth factor 1 (IGF-1). Clinical research has examined its effects on hormone secretion and body composition. In a study of older adults, increased fat-free mass did not translate into improved strength or physical function. Ibutamoren is not a selective androgen receptor modulator (SARM).
Product Specifications:
Commercial name: Ibutamoren
Listed compound: MK-677
Declared strength: 10mg per tablet
Format: Tablets
Package contents: 50 tablets
Important Note:
Ibutamoren can increase appetite, cause fluid retention and muscle pain, and raise blood glucose while reducing insulin sensitivity. The FDA has also identified a potential risk of congestive heart failure in certain individuals.
All products sold by ORYVION are intended for laboratory research purposes only and are not approved for human consumption, medical use, or veterinary applications. These compounds are not classified as dietary supplements or pharmaceuticals.
ORYVION operates strictly within the legal frameworks of the jurisdictions in which it conducts business. Sales are limited to countries and regions where the possession and use of research chemicals are permitted by law. It is the sole responsibility of the purchaser to ensure compliance with local, national, and international laws and regulations.
By purchasing, the customer affirms that they are at least 21 years of age, legally authorized to receive such materials, and fully aware of their intended use. ORYVION disclaims all liability for misuse, improper handling, or any consequences resulting from non-compliant use of these products.
ORYVION complies with relevant provisions under EU’s Pharmaceutical and Medical Device Act, as well as applicable international guidelines regarding non-pharmaceutical research compounds.